When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.

The US Food and Drug Administration (FDA) has granted traditional approval to Merck & Co’s (NYSE: MRK) Keytruda ...

Adding an immune checkpoint inhibitor (ICI) to chemotherapy for advanced prostate cancer failed to improve survival as ...

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

Learn how long you'll likely receive Keytruda infusions, what factors can affect your treatment length, and what to expect after you stop treatment.

A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously ...

Keytruda (pembrolizumab) is prescribed to treat melanoma and other conditions by reviving the body’s immune system. Your response to this drug may vary based on your medical history, diagnosis ...

The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company’s MHC Class II agonist, eftilagimod alfa (efti) in combination with MSD’s (Merck & ...

Among patients with unresectable, non-metastatic hepatocellular carcinoma, treatment with Lenvima (Lenvatinib) plus Keytruda (pembrolizumab) in combination with transarterial chemoembolization (TACE) ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of ...

On March 19, the Food and Drug Administration granted traditional approval to pembrolizumab, or Keytruda, marketed by Merck (MRK), with ...